European (EU) H2020 funded ORGANTRANS project is set to develop a platform with corresponding technologies for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation.
Brief Description & Goal
Coordinated by CSEM, eight consortium members will create a standardized and automated tissue preparation and maturation platform, which will provide patients with End-Stage Liver Disease (ESLD) an alternative to donor organ transplants. Adult stem cells can be taken from healthy residual liver tissue of patients, isolated and even organized into organoids. These are then assembled by printing and allowed to mature in a unique combination bioreactor. This procedure enables the production of a personalized tissue engineered autologous liver that is tailored to the patient. The platform technologies can later be scaled up to other organ systems and therapeutic approaches in regenerative medicine.
The aim of the project is creating an alternative to organ donation for liver repair and the translation of the novel 3D liver tissue construct for transplantation into clinical application.
Kugelmeiers has long-standing experience in the field of scaffold-free 3D cell culture and the production, handling and cultivation of (stem cell-based) spheroids. With the Sphericalplate 5D, the company has developed a translational platform for upscaling of standardized spheroids of any type and size. In addition, an internal team of regulatory specialists is accompanying the project in order to prepare the approval of the developed medical devices and cell products as a clinical therapy for the treatment of ESLD.
|CSEM (Project coordinator)
|University of Utrecht
|Leibniz Institute for Interactive Materials
|King’s College London
|Amires SRO (Project Management)